Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

ADC Therapeutics SA

NYSE: ADCT · Life Sciences · 4 alerts · CIK 1771910

Share price
$1.25Close, Nov 16
Market cap
$160M
Shares outstanding
127.67MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All ADC Therapeutics SA filings on SEC EDGAR ↗

4:12 PM ET 10-Q
Financial Results

ADC Therapeutics Q3 2026 Results: Net Loss of $25.3M, Loss Narrows

ADC Therapeutics reported total revenue of $61.8 million for the nine months ended September 30, 2026, compared to $58.3 million in the prior year, driven primarily by growth in net product revenues. The company significantly reduced its operating expenses from $161.9 million to $126.8 million year-over-year, largely due to lower research and development costs and reduced restructuring charges.

Key figure
Net loss $25.3M
8:06 AM ET 8-K
Financial Results

ADC Therapeutics Financial Results

ADC Therapeutics reported Q3 2026 net product revenue of $21 million and highlighted a strategic financial restructuring completed in October that extended its cash runway into 2029. The company also noted multiple upcoming data presentations for ZYNLONTA at the ASH 2026 annual meeting.

Term
Q3 2026

“During the third quarter, we made meaningful progress toward strengthening ADC Therapeutics' balance sheet and increasing strategic optionality while advancing clinical opportunities for ZYNLONTA®.”

Ameet Mallik, Chief Executive Officer of ADC Therapeutics

“The upcoming LOTIS-7 Phase 1b and marginal zone lymphoma IIT data at ASH highlights the potential for ZYNLONTA to play an important role in the treatment of r/r DLBCL and indolent lymphomas.”

Mohamed Zaki, M.D., Ph.D., Chief Medical Officer of ADC Therapeutics
4:02 PM ET 8-K
Clinical Trial Data

ADC Therapeutics Clinical Trial Data

ADC Therapeutics announced updated clinical data for ZYNLONTA from several trials, including the LOTIS-7 Phase 1b study which showed an 88.7% overall response rate and 75.3% complete response rate in relapsed or refractory large B-cell lymphoma. The data, which will be presented at the ASH Annual Meeting, also highlighted a 93% ORR in marginal zone lymphoma and results from the Phase 3 LOTIS-5 study. These findings support the company's plans to advance ZYNLONTA into Phase 3 studies for expanded indications.

6:27 AM ET 8-K
Capital Raise

ADC Therapeutics Capital Raise of $86.6M

ADC Therapeutics entered into securities purchase agreements for a $86.6 million private placement (PIPE) involving the sale of 12.9 million common shares and 48.1 million pre-funded warrants. The financing included participation from new investor Bain Capital Life Sciences and existing investors Redmile, TCGX, and Nantahala Capital. Proceeds will be used to fund ZYNLONTA pipeline studies and extend the company's cash runway into 2029.

Value
$86.6M
Counterparty
Bain Capital Life Sciences

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.